Boehringer to use Circuit optogenetics technology to develop new obesity drugs
The earlier collaboration between the two firms focused on the discovery of new treatments for neuropsychiatric disorders, while the new three-year deal will focus on investigating new medicines
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.